SE-DR Affinity Peptides for Rheumatic Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for rheumatic diseases, particularly rheumatoid arthritis, face challenges in balancing clinical safety and effectiveness, especially for tuberculosis-positive patients or those complicated with hepatitis B, due to limited drug choices and increased risks of medication.
Innovation Solution
The use of SE-DR affinity peptides, such as FNS007, which act as antigen-specific therapeutics by competitively inhibiting the binding of rheumatic disease-related antigen peptides to HLA-DR molecules, thereby inhibiting the activation of disease-specific autoreactive T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-rheumatic drugs are used to treat rheumatoid arthritis, then therapeutic effectiveness is improved, but the risk of tuberculosis activation and hepatitis B recurrence increases
Solution Approach 1:
The patent segments the immune system's T cell activation process into specific components (TCR signaling, co-stimulation pathways) and targets only the pathogenic autoreactive T cells through antigen-specific peptides, rather than broadly suppressing all immune responses. This selective approach treats rheumatoid arthritis while preserving protection against tuberculosis and hepatitis B.
Solution Approach 2:
The patent uses antigen-specific peptides as intermediaries that bind to HLA-DR molecules and block the interaction between autoreactive T cell receptors and self-antigens. These peptides act as mediators that specifically inhibit pathogenic immune responses without affecting the broader immune system's ability to combat infections.
2Reliability
If immunosuppressive therapy is intensified to control rheumatoid arthritis, then disease activity is reduced, but susceptibility to infections increases
Solution Approach 1:
The patent applies local quality by directing immunosuppression only to the specific pathological process (autoreactive T cell activation in rheumatoid arthritis) while leaving other immune functions intact. The antigen-specific peptides selectively modulate immune responses at the molecular level where they are needed, preserving systemic immune competence.
Solution Approach 2:
The patent employs partial action by using only the specific portion of immune suppression necessary to block pathogenic T cell activation, rather than applying broad immunosuppression. This targeted approach achieves sufficient disease control with minimal impact on overall immune function and infection resistance.
3Reliability
If broad immunosuppression is used to treat rheumatoid arthritis, then inflammation is reduced, but the distinction between protective and pathogenic immune responses is lost
Solution Approach 1:
The patent extracts and isolates the specific pathogenic component (autoreactive T cell activation through HLA-DR presentation) from the broader immune system. By using antigen-specific peptides that target only this pathway, the treatment removes the harmful immune activation while preserving the adaptive and protective immune responses.
Solution Approach 2:
Instead of suppressing immune responses broadly as in conventional therapy, the patent inverts the approach by using antigen-specific peptides that actively promote tolerance to self-antigens while leaving other immune functions untouched. This inverted strategy maintains immune discrimination capability while controlling inflammation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
SE-DR affinity peptides effectively reduce the incidence of tuberculosis and hepatitis B activation, while safely controlling rheumatoid arthritis, even in patients with pre-existing tuberculosis or hepatitis B, and can maintain therapeutic effects after drug discontinuation.
Implementation Method 1
SE-DR affinity peptides, such as FNS007, which act as antigen-specific therapeutics by competitively inhibiting the binding of rheumatic disease-related antigen peptides to HLA-DR molecules
Data Source
AI summary
The present invention provides the use of SE-DR (an HLA-DR molecule containing the shared epitope) affinity peptides in the preparation of a medicament for the treatment of rheumatic diseases in the rheumatoid patients being tuberculosis-positive and/or complicated with hepatitis B. The invention solves the problem of limited choice of drugs for the patients with the rheumatic disease. The invention also provides a pharmaceutical composition comprising an SE-DR affinity peptide and a non-antigen-specific anti-rheumatic drug, and its use in the preparation of a medication for the treatment of various types of rheumatic diseases. The pharmaceutical composition can quickly delay the procession of the rheumatic disease, and can achieve sustained remission after the drug tapering or discontinuation, so as to completely control the rheumatic diseases.